JP2015510515A5 - - Google Patents

Download PDF

Info

Publication number
JP2015510515A5
JP2015510515A5 JP2014557739A JP2014557739A JP2015510515A5 JP 2015510515 A5 JP2015510515 A5 JP 2015510515A5 JP 2014557739 A JP2014557739 A JP 2014557739A JP 2014557739 A JP2014557739 A JP 2014557739A JP 2015510515 A5 JP2015510515 A5 JP 2015510515A5
Authority
JP
Japan
Prior art keywords
alkyl
group
substituted
cycloalkyl
coor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014557739A
Other languages
English (en)
Japanese (ja)
Other versions
JP6155285B2 (ja
JP2015510515A (ja
Filing date
Publication date
Priority claimed from US13/760,726 external-priority patent/US8906889B2/en
Application filed filed Critical
Publication of JP2015510515A publication Critical patent/JP2015510515A/ja
Publication of JP2015510515A5 publication Critical patent/JP2015510515A5/ja
Application granted granted Critical
Publication of JP6155285B2 publication Critical patent/JP6155285B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014557739A 2012-02-15 2013-02-13 Hiv成熟阻害活性のあるc−3シクロアルケニルトリテルペノイド Expired - Fee Related JP6155285B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261599040P 2012-02-15 2012-02-15
US61/599,040 2012-02-15
US13/760,726 US8906889B2 (en) 2012-02-15 2013-02-06 C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity
US13/760,726 2013-02-06
PCT/US2013/025897 WO2013123019A1 (en) 2012-02-15 2013-02-13 C-3 cycloalkenyl triterpenoids with hiv maturation inhibitory activity

Publications (3)

Publication Number Publication Date
JP2015510515A JP2015510515A (ja) 2015-04-09
JP2015510515A5 true JP2015510515A5 (enExample) 2016-03-17
JP6155285B2 JP6155285B2 (ja) 2017-06-28

Family

ID=48946098

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014557739A Expired - Fee Related JP6155285B2 (ja) 2012-02-15 2013-02-13 Hiv成熟阻害活性のあるc−3シクロアルケニルトリテルペノイド

Country Status (26)

Country Link
US (1) US8906889B2 (enExample)
EP (1) EP2814834B1 (enExample)
JP (1) JP6155285B2 (enExample)
KR (1) KR20140123584A (enExample)
CN (2) CN106046106A (enExample)
AR (1) AR089996A1 (enExample)
AU (1) AU2013221725B2 (enExample)
BR (1) BR112014019672A8 (enExample)
CA (1) CA2864656A1 (enExample)
CL (1) CL2014002141A1 (enExample)
CO (1) CO7061077A2 (enExample)
EA (1) EA024361B1 (enExample)
ES (1) ES2656984T3 (enExample)
HK (1) HK1204608A1 (enExample)
IL (1) IL234077A (enExample)
MX (1) MX2014009235A (enExample)
MY (1) MY166793A (enExample)
NZ (1) NZ631408A (enExample)
PE (1) PE20142315A1 (enExample)
PH (1) PH12014501816A1 (enExample)
PT (1) PT2814834T (enExample)
SG (1) SG11201404748XA (enExample)
TW (1) TW201336863A (enExample)
UY (1) UY34627A (enExample)
WO (1) WO2013123019A1 (enExample)
ZA (1) ZA201406724B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
US20140221361A1 (en) 2013-02-06 2014-08-07 Bristol-Myers Squibb Company C-19 modified triterpenoids with hiv maturation inhibitory activity
PL3129392T3 (pl) 2014-04-11 2021-04-06 VIIV Healthcare UK(No.4) Limited Triterpenoidy o aktywności hamującej dojrzewanie hiv, podstawione w pozycji 3 niearomatycznym pierścieniem zawierającym podstawnik fluorowcoalkilowy
WO2015195776A1 (en) 2014-06-19 2015-12-23 Bristol-Myers Squibb Company Betulinic acid derivatives with hiv maturation inhibitory activity
KR20170092581A (ko) 2014-11-14 2017-08-11 비브 헬스케어 유케이 (넘버5) 리미티드 C17-아릴 치환된 베툴린산 유사체
BR112017009853A2 (pt) * 2014-11-14 2018-01-16 Viiv Healthcare Uk No 5 Ltd composto, composição, uso de uma quantidade melhoradora de hiv de um composto
BR112017009850A2 (pt) * 2014-11-14 2018-01-16 Viiv Healthcare Uk No 5 Ltd composto, composição, e, uso de uma quantidade melhoradora de hiv de um composto
WO2016168447A1 (en) * 2015-04-14 2016-10-20 VIIV HEALTHCARE (No.4) LIMITED Methods of producing an hiv maturation inhibitor
KR20180028535A (ko) 2015-07-28 2018-03-16 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드 Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체
EP3328876A1 (en) 2015-07-28 2018-06-06 Glaxosmithkline Intellectual Property (No. 2) Limited Betuin derivatives for preventing or treating hiv infections
AU2016327169A1 (en) 2015-09-24 2018-04-12 Glaxosmithkline Intellectual Property (No.2) Limited Compounds with hiv maturation inhibitory activity
JP2019502728A (ja) * 2016-01-20 2019-01-31 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Hiv成熟阻害活性を有するルパンのアミン誘導体
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
CN106905264B (zh) * 2017-04-12 2019-06-07 连云港杰瑞药业有限公司 一种合成阿扎拉韦中间体的方法
WO2019055280A1 (en) 2017-09-13 2019-03-21 Emmyon, Inc. DIETHANOLAMINE SALTS AND URSOLIC ACID MORPHOLIN
EP3784349B1 (en) 2018-04-24 2023-12-27 VIIV Healthcare UK (No.5) Limited Compounds with hiv maturation inhibitory activity
CN109705189B (zh) * 2018-12-29 2020-06-05 中国医学科学院药用植物研究所 具有式i所示结构的三萜衍生物及其制备方法和应用
US12275712B2 (en) 2019-02-11 2025-04-15 Hetero Labs Limited Triterpene derivatives as HIV inhibitors
WO2020229398A1 (de) 2019-05-14 2020-11-19 Bayer Aktiengesellschaft (1-alkenyl)-substituierte pyrazole und triazole als schädlingsbekämpfungsmittel

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
US5869535A (en) 1995-03-21 1999-02-09 The Board Of Trustees Of The University Of Illinois Method and composition for selectively inhibiting melanoma
US5962527A (en) 1995-03-21 1999-10-05 The Board Of Trustees Of The University Of Illinois Method and composition for treating cancers
US5679828A (en) 1995-06-05 1997-10-21 Biotech Research Labs, Inc. Betulinic acid and dihydrobetulinic acid derivatives and uses therefor
US20040110785A1 (en) 2001-02-02 2004-06-10 Tao Wang Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives
US7365221B2 (en) 2002-09-26 2008-04-29 Panacos Pharmaceuticals, Inc. Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof
WO2004089357A2 (en) 2003-04-02 2004-10-21 Regents Of The University Of Minnesota Anti-fungal formulation of triterpene and essential oil
US7745625B2 (en) 2004-03-15 2010-06-29 Bristol-Myers Squibb Company Prodrugs of piperazine and substituted piperidine antiviral agents
AU2005224260A1 (en) 2004-03-17 2005-09-29 Panacos Pharmaceuticals, Inc. Pharmaceuticals salts of 3-O-(3',3'-dimethylsuccinyl) betulinic acid
TW200628161A (en) 2004-11-12 2006-08-16 Panacos Pharmaceuticals Inc Novel betulin derivatives, preparation thereof and use thereof
WO2008127364A2 (en) 2006-10-13 2008-10-23 Myriad Genetics, Inc. Antiviral compounds and use thereof
US20110144069A1 (en) 2006-10-16 2011-06-16 Myriad Genetics, Incorporated Compounds for treating viral infections
WO2009020732A1 (en) 2007-08-03 2009-02-12 Advanced Life Sciences, Inc. Lupane-type triterpenoids modified at 30-position and analogues thereof
EP2250185A4 (en) * 2008-01-03 2011-11-16 Virochem Pharma Inc NEW LUPANDERIVATE
AU2009214779A1 (en) 2008-02-14 2009-08-20 Virochem Pharma Inc. Novel 17beta lupane derivatives
US9067966B2 (en) 2009-07-14 2015-06-30 Hetero Research Foundation, Hetero Drugs Ltd. Lupeol-type triterpene derivatives as antivirals
MA33926B1 (fr) 2009-12-17 2013-01-02 Merck Sharp & Dohme Aminopyrimidines en tant qu'inhibiteurs de la syk
ES2548905T3 (es) 2010-06-04 2015-10-21 Bristol-Myers Squibb Company Amidas C-28 de derivados del ácido betulínico C-3 modificados como inhibidores de la maduración del VIH
EP2576585B8 (en) * 2010-06-04 2016-12-21 VIIV Healthcare UK (No.5) Limited Modified c-3 betulinic acid derivatives as hiv maturation inhibitors
AP2013006706A0 (en) 2010-07-02 2013-02-28 Gilead Sciences Inc Napht-2-ylacetic acid derivatives to treat AIDS
SI2670764T1 (sl) * 2011-01-31 2016-03-31 Bristol-Myers Squibb Company C-28 amini derivatov c-3 modificirane betulinske kisline inhibitorjev zorenja hiv
CA2826113C (en) * 2011-01-31 2018-09-04 Bristol-Myers Squibb Company C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity
MX2014002936A (es) 2011-09-21 2014-04-25 Bristol Myers Squibb Co Nuevos derivados de acido betulinico con actividad antiviral.
US8889854B2 (en) 2012-05-07 2014-11-18 Bristol-Myers Squibb Company C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity
US20140221361A1 (en) * 2013-02-06 2014-08-07 Bristol-Myers Squibb Company C-19 modified triterpenoids with hiv maturation inhibitory activity

Similar Documents

Publication Publication Date Title
JP2015510515A5 (enExample)
JP2014503595A5 (enExample)
JP2016509062A5 (enExample)
JP2014507422A5 (enExample)
JP2016507558A5 (enExample)
JP2013527243A5 (enExample)
JP2013527242A5 (enExample)
JP2014526554A5 (enExample)
JP2016006053A5 (enExample)
JP2017531038A5 (enExample)
FI4219508T3 (fi) Substituoitu polysyklinen pyridonijohdannainen ja sen aihiolääke
JP2019504104A5 (enExample)
EA201891876A1 (ru) Тетрациклические пиридоновые соединения в качестве противовирусных средств
MX384836B (es) Agentes antivirales contra la hepatitis b
JP2017523225A5 (enExample)
JP2013032389A5 (enExample)
JP2012144574A5 (enExample)
JP2018510139A5 (enExample)
JP2017537940A5 (enExample)
JP2014500861A5 (enExample)
JP2019524883A5 (enExample)
JP2015509983A5 (enExample)
JP2015024998A5 (enExample)
AR099632A1 (es) Tratamiento de una infección viral de hepatitis c, que usa una combinación de compuestos
MX2018009944A (es) Procedimiento para la preparacion del acido 4-fenil-5-alcoxicarbon il-2-tiazol-2-il-1,4-dihidropirimidin-6-il-[metil]3-oxo-5,6,8,8a- tetrahidro-1h-imidazo[1,5a]pirazin-2-il-carboxilico.